Elicio Therapeutics
ELTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +56.1% in FY2025
Robert Connelly is the CEO of Elicio Therapeutics and was paid $1.9M in FY2025 (Dec), down 7%.
Pay$100 in the stock at the end of FY21 → $27
Executives3
See all- 1Robert ConnellyPresident, Chief Executive Officer, and DirectorFY2025
- 2Preetam Shah, Ph.D.Chief Strategy and Financial Officer and TreasurerFY2025
- 3Christopher Haqq, M.D., Ph.D.Executive Vice President, Head of Research and Development and Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allElicio Therapeutics paid its 3 named executives $4.3M in total in FY2025 (Dec). CEO Robert Connelly was paid $1.9M of that.
| Name | |||
|---|---|---|---|
| Robert ConnellyPresident, Chief Executive Officer, and Director | |||
| Preetam Shah, Ph.D.Chief Strategy and Financial Officer and Treasurer | Not disclosed | ||
| Christopher Haqq, M.D., Ph.D.Executive Vice President, Head of Research and Development and Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Elicio Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Julian Adams, Ph.D.Chair · 2 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Allen R. Nissenson, M.D.Director · 2 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance (Chair)—Paid as an executive
- Carol AsheDirector · 2 yr on the boardIndependentAudit, Compensation (Chair), Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Oct 9, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 9, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | Sep 27, 2024 | FY2023 |
| Annual report | 10-K | Mar 29, 2024 | FY2023 |
